Tagged IRWD


Ironwood Files Form 10 for Cyclerion

          , 2019 Dear Future Cyclerion Shareholder:         On behalf of the entire Cyclerion team, I am pleased to welcome you as a future shareholder of our new company.         Cyclerion will be a clinical-stage biopharmaceutical company focused on harnessing the full therapeutic potential of nitric oxide signaling through development of next-generation soluble guanylate cyclase, or sGC, stimulators….


Ironwood Pharma to Split into Two

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that its Board of Directors has authorized an intent to separate into two independent, publicly traded companies (Ironwood and “R&D Co.”). The separation is expected to be completed in the first half of 2019 and is anticipated to be tax-free to Ironwood shareholders….